Skip to main content

Table 2 Cytotoxicity of compounds 9, 10, 11a, 11b, 12, 13, and 14 against hepatocellular carcinoma cell line HePG2

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL

Viability (%)/compound

9

10

11a

11b

12

13

14

500

8.43

8.32

23.84

10.32

4.29

4.83

3.74

250

15.82

16.01

48.67

19.47

11.82

12.56

8.91

125

24.67

23.65

72.89

27.93

20.49

19.74

14.82

62.5

30.93

29.86

90.31

38.76

26.54

28.63

20.94

31.25

41.28

37.40

98.16

50.37

32.75

35.16

25.86

15.6

48.71

46.89

100

68.24

41.87

46.29

31.43

7.8

62.39

58.62

100

81.49

55.46

57.18

37.82

3.9

78.24

73.94

100

90.65

73.82

70.42

45.27

2

88.65

81.47

100

97.34

81.46

83.29

50.94

1

94.27

89.53

100

100

88.73

89.64

62.35

0

100

100

100

100

100

100

100